In this brief report, we offer a concise overview on current cancer epidemiology garnered
from the official databases of World Health Organization and American Cancer Society and …

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for
cancer and other diseases. Liquid biopsy allows minimally invasive molecular …

Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based
genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic …

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to
identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of …

Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Circulating tumor cells (CTCs) carry a wealth of information on primary and metastatic
tumors critical for precise cancer detection, monitoring, and treatment. Numerous …

Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer
patients to provide information regarding the genetic landscape of the cancer. It is emerging …

Purpose: Many patients with locoregionally advanced human papillomavirus–negative head
and neck squamous cell carcinoma (HNSCC) relapse. ctDNA has the potential to identify …

Colorectal cancer (CRC) arise from multi-step carcinogenesis due to genetic mutations and
epigenetic modifications of human genome. Genetic mutations and epigenetic modifications …

Current (high throughput omics-based) data support the model that human (malignant) germ
cell tumors are not initiated by somatic mutations, but, instead through a defined locked …